These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17325852)

  • 21. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
    Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
    Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
    Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
    Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of nelarabine in indolent leukemias.
    Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
    J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
    Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
    Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
    Duvic M; Kim YH; Zinzani PL; Horwitz SM
    Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.
    Espinoza-Zamora JR; Labardini-Méndez J; Sosa-Espinoza A; López-González C; Vieyra-García M; Candelaria M; Lozano-Zavaleta V; Toledano-Cuevas DV; Zapata-Canto N; Cervera E; Dueñas-González A
    Expert Opin Investig Drugs; 2017 Apr; 26(4):481-487. PubMed ID: 28277033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nelarabine.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
    Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
    Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
    Wollina U; Dummer R; Brockmeyer NH; Konrad H; Busch JO; Kaatz M; Knopf B; Koch HJ; Hauschild A
    Cancer; 2003 Sep; 98(5):993-1001. PubMed ID: 12942567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Holkova B; Yazbeck V; Kmieciak M; Bose P; Ma S; Kimball A; Tombes MB; Shrader E; Wan W; Weir-Wiggins C; Singh A; Hogan KT; Conine S; Sankala H; Roberts JD; Shea TC; Grant S
    Leuk Lymphoma; 2017 Jun; 58(6):1349-1357. PubMed ID: 28103725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.